Table 2. Characteristics of the whole study population, and stratified by the HIV status of the participants.
| ALL N = 13771 | HIV Negative N = 11263 (82%) | HIV Positive N = 2508 (18%) | p-value | |
|---|---|---|---|---|
| Sex (Female) | 9246 (67.2%) | 7520 (66.9%) | 1726 (68.9%) | 0.054 |
| Age at diabetes ascertainment (Years) | 52.0 [44.0;59.0] | 53.0 [46.0;61.0] | 46.0 [39.0;52.0] | <0.001 |
| Age categories | <0.001 | |||
| 18–39 | 2110 (15.3%) | 1445 (12.8%) | 665 (26.5%) | |
| 40–49 | 3718 (27.0%) | 2742 (24.3%) | 976 (38.9%) | |
| 50–59 | 4576 (33.2%) | 3906 (34.7%) | 670 (26.7%) | |
| 60–69 | 2357 (17.1%) | 2191 (19.5%) | 166 (6.6%) | |
| 70–79 | 805 (5.8%) | 779 (6.9%) | 26 (1.0%) | |
| > = 80 | 205 (1.5%) | 200 (1.8%) | 5 (0.2%) | |
| Baseline HbA1c (%) | 8.5 [7.0;11.1] | 8.6 [7.0;11.1] | 8.4 [6.9;10.9] | 0.008 |
| Baseline HbA1c < 7% | 2820 (24.5%) | 2268 (24.0%) | 552 (26.4%) | 0.023 |
| Last HbA1c (%) | 9.5 [7.2;12.7] | 9.1 [7.1;12.0] | 12.1 [7.9;15.0] | <0.001 |
| Last HbA1c < 7% | 2928 (21.3%) | 2509 (22.3%) | 419 (16.7%) | <0.001 |
| Patient outcome (Deceased) | 631 (4.6%) | 488 (4.3%) | 143 (5.7%) | 0.004 |
| Ever started diabetes treatment | 11745 (85.3%) | 9631 (85.5%) | 2114 (84.3%) | 0.126 |
| Linkage to diabetes a treatment | 10707 (91.2%) | 8913 (92.5%) | 1794 (84.9%) | <0.001 |
| Linkage to HbA1c testing b | 9264 (67.3%) | 7580 (67.3%) | 1684 (67.2%) | 0.909 |
| Ever had Tuberculosis | 1839 (13.4%) | 1039 (9.2%) | 800 (31.9%) | <0.001 |
| Tuberculosis-Diabetes comorbidity | 1008 (55.9%) | 627 (62.0%) | 381 (48.2%) | <0.001 |
a. Proportions of patients having a record of diabetes drugs being prescribed within one year of their last recorded diabetes-related hospital encounter (calculated from those who had ever started diabetes treatment)
b. Proportion of patients having a recorded HbA1c laboratory test result within one year of the last recorded diabetes related hospital encounter